News and Views
Nature Chemical Biology 4, 648 - 649 (2008)
doi:10.1038/nchembio1108-648
Killing two kinase families with one stone
Benoit Bilanges1, Neil Torbett2 & Bart Vanhaesebroeck1
- Benoit Bilanges and Bart Vanhaesebroeck are in the Centre for Cell Signalling, Institute of Cancer, Barts and The London School of Medicine & Dentistry, Charterhouse Square, London EC1M 6BQ, UK. e-mail: bart.vanh@qmul.ac.uk
- Neil Torbett is at Piramed Pharma, 957 Buckingham Avenue, Slough, Berkshire SL1 4NL, UK.
Abstract
Multitargeted protein kinase inhibitors have shown great promise in cancer therapy, but the selectivity profiles of these compounds have largely relied on serendipity or 'off-target' activities rather than rational drug design. Purposefully designed compounds with activity against multiple target kinases bring us a step closer to personalized medicine.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinasesNature Chemical Biology Article (01 Nov 2008)
